A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry) - Trial NCT06412250
Access comprehensive clinical trial information for NCT06412250 through Pure Global AI's free database. This phase not specified trial is sponsored by Translumina Therapeutics LLP and is currently Recruiting. The study focuses on Cardiovascular Diseases. Target enrollment is 2000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Translumina Therapeutics LLP
Timeline & Enrollment
N/A
Jan 10, 2024
May 01, 2026
Primary Outcome
Ischemic endpoint,Bleeding endpoint
Summary
The objective of this post marketing observational registry is to evaluate clinical outcomes
 (safety and performance) in an all-comers population with coronary artery disease (CAD)
 treated with the Polymer Free Sirolimus Eluting Coronary Stent Vivo ISAR and planned for an
 abbreviated (≤ 3 months) dual antiplatelet therapy (DAPT) regimen.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06412250
Non-Device Trial